Description:
CDC researchers have developed technology for sero-diagnosis of typically symptomless latent stage tuberculosis disease, posing a threat to individuals under immunosuppressive or anti-inflammatory therapies. Specifically, this diagnostic approach exploits
M. tuberculosis secreted latency specific antigens, such as alpha-crystallin, in the blood or urine of patients. This type of test could easily be developed into an inexpensive dip-stick format with high specificity (no cross-reactivity with other mycobacteria), rapidity, and sensitivity (fewer bacteria needed for a positive identification). Because secreted antigens are recognized more readily by the immune system, serum-derived antibodies to these antigens can correspondingly be used for diagnostic or research use.